Management of Adverse Effects of New Monoclonal Antibody Treatments in Acute Lymphoblastic Leukemia

Overview

Journal Drugs Context

Specialty Pharmacology

Date 2020 Oct 28

PMID 33110433

Citations 5

Authors

Diego Conde-Royo

Luis Miguel Juarez-Salcedo

Samir Dalia

Affiliations

Soon will be listed here.

Abstract

Therapeutic options for relapsed/refractory B-cell acute lymphoblastic leukemia have evolved in the past few years. The FDA has approved three novel therapies for this disease: inotuzumab ozogamicin (an anti-CD22 antibody-drug conjugate), blinatumomab (a bispecific T-cell engager), and chimeric antigen receptor T-cell therapy. Although these novel immunotherapies have revolutionized the therapeutic landscape, it is important to understand the crucial aspects of administration, especially toxicity. In this article, we review the unique toxicities and adverse effects of blinatumomab and inotuzumab ozogamicin and provide recommendations for prevention of adverse effects as well as the management options for each medication.

Citing Articles

Exploratory biomarker analysis from a phase III study of the PI3K inhibitor, copanlisib, in combination with rituximab in patients with indolent non-Hodgkin lymphoma, a retrospective study.

Chaturvedi S, Weispfenning A, Descamps T, Bellinvia S, Bauer D, Du R Clin Transl Oncol. 2025; .

PMID: 39984775 DOI: 10.1007/s12094-025-03869-2.

Updates on the mechanisms of toxicities associated with monoclonal antibodies targeting growth factor signaling and immune cells in cancer.

Park M, Kim J Toxicol Res. 2024; 40(3):335-348.

PMID: 38911540 PMC: 11187026. DOI: 10.1007/s43188-024-00233-4.

Neurologic Complications of Cancer Immunotherapy.

Alsalem A, Scarffe L, Briemberg H, Aaroe A, Harrison R Curr Oncol. 2023; 30(6):5876-5897.

PMID: 37366923 PMC: 10297570. DOI: 10.3390/curroncol30060440.

Drug-Induced Cardiotoxicity in Children During the Past 30 Years: A Bibliometric Study and Visualization Analysis.

Wu M, Yang Y, Cao M, Liu T, Tian Y, Zhao Z Med Sci Monit. 2023; 29:e938673.

PMID: 36806177 PMC: 9951546. DOI: 10.12659/MSM.938673.

Bispecific Antibodies in Cancer Immunotherapy: A Novel Response to an Old Question.

Ordonez-Reyes C, Garcia-Robledo J, Chamorro D, Mosquera A, Sussmann L, Ruiz-Patino A Pharmaceutics. 2022; 14(6).

PMID: 35745815 PMC: 9229626. DOI: 10.3390/pharmaceutics14061243.

References

Jain T, Litzow M . No free rides: management of toxicities of novel immunotherapies in ALL, including financial. Blood Adv. 2018; 2(22):3393-3403. PMC: 6258912. DOI: 10.1182/bloodadvances.2018020198. View

Kantarjian H, Thomas D, Jorgensen J, Kebriaei P, Jabbour E, Rytting M . Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013; 119(15):2728-36. PMC: 3720844. DOI: 10.1002/cncr.28136. View

Coiffier B, Altman A, Pui C, Younes A, Cairo M . Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008; 26(16):2767-78. DOI: 10.1200/JCO.2007.15.0177. View

Klinger M, Zugmaier G, Nagele V, Goebeler M, Brandl C, Stelljes M . Adhesion of T Cells to Endothelial Cells Facilitates Blinatumomab-Associated Neurologic Adverse Events. Cancer Res. 2019; 80(1):91-101. DOI: 10.1158/0008-5472.CAN-19-1131. View

Curigliano G, Spitaleri G, de Braud F, Cardinale D, Cipolla C, Civelli M . QTc prolongation assessment in anticancer drug development: clinical and methodological issues. Ecancermedicalscience. 2012; 3:130. PMC: 3223992. DOI: 10.3332/ecancer.2009.130. View

Mehta H, Malandra M, Corey S . G-CSF and GM-CSF in Neutropenia. J Immunol. 2015; 195(4):1341-9. PMC: 4741374. DOI: 10.4049/jimmunol.1500861. View

Drgona L, Gudiol C, Lanini S, Salzberger B, Ippolito G, Mikulska M . ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30,.... Clin Microbiol Infect. 2018; 24 Suppl 2:S83-S94. DOI: 10.1016/j.cmi.2018.03.022. View

Paydas S, Ergin M, Baslamisli F, Yavuz S, Zorludemir S, Sahin B . Bone marrow necrosis: clinicopathologic analysis of 20 cases and review of the literature. Am J Hematol. 2002; 70(4):300-5. DOI: 10.1002/ajh.10114. View

Kantarjian H, Stein A, Gokbuget N, Fielding A, Schuh A, Ribera J . Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N Engl J Med. 2017; 376(9):836-847. PMC: 5881572. DOI: 10.1056/NEJMoa1609783. View

10.

Kebriaei P, Cutler C, de Lima M, Giralt S, Lee S, Marks D . Management of important adverse events associated with inotuzumab ozogamicin: expert panel review. Bone Marrow Transplant. 2018; 53(4):449-456. PMC: 5897380. DOI: 10.1038/s41409-017-0019-y. View

11.

Kantarjian H, Ravandi F, Short N, Huang X, Jain N, Sasaki K . Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2018; 19(2):240-248. PMC: 11537312. DOI: 10.1016/S1470-2045(18)30011-1. View

12.

Dinner S, Liedtke M . Antibody-based therapies in patients with acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2018; 2018(1):9-15. PMC: 6246018. DOI: 10.1182/asheducation-2018.1.9. View

13.

Hibma J, Kantarjian H, DeAngelo D, Boni J . Effect of inotuzumab ozogamicin on the QT interval in patients with haematologic malignancies using QTc-concentration modelling. Br J Clin Pharmacol. 2018; 85(3):590-600. PMC: 6379221. DOI: 10.1111/bcp.13832. View

14.

Raponi S, De Propris M, Intoppa S, Milani M, Vitale A, Elia L . Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk Lymphoma. 2011; 52(6):1098-107. DOI: 10.3109/10428194.2011.559668. View

15.

Coppell J, Richardson P, Soiffer R, Martin P, Kernan N, Chen A . Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant. 2009; 16(2):157-68. PMC: 3018714. DOI: 10.1016/j.bbmt.2009.08.024. View

16.

Scheuermann R, Racila E . CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Leuk Lymphoma. 1995; 18(5-6):385-97. DOI: 10.3109/10428199509059636. View

17.

Freifeld A, Bow E, Sepkowitz K, Boeckh M, Ito J, Mullen C . Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011; 52(4):e56-93. DOI: 10.1093/cid/cir073. View

18.

Mohty M, Malard F, Abecassis M, Aerts E, Alaskar A, Aljurf M . Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2016; 51(7):906-12. PMC: 4935979. DOI: 10.1038/bmt.2016.130. View

19.

Topp M, Gokbuget N, Zugmaier G, Klappers P, Stelljes M, Neumann S . Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014; 32(36):4134-40. DOI: 10.1200/JCO.2014.56.3247. View

20.

Darvishi B, Farahmand L, Jalili N, Majidzadeh-A K . Blinatumomab provoked fatal heart failure. Int Immunopharmacol. 2016; 41:42-46. DOI: 10.1016/j.intimp.2016.10.017. View